South San Francisco, CA, United States
South San Francisco, CA, United States

Time filter

Source Type

In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.


Patent
Theravance | Date: 2016-10-10

In one aspect, the invention relates to compounds having the formula: where R^(1), R^(2), R^(3), X, R^(4), R^(5), and R^(6 )are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.


The invention relates to benzimidazole-carboxamide 5-HT_(4 )receptor agonist compounds of formula (I) wherein R^(1 )and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT_(4 )receptor activity, and processes and intermediates useful for preparing such compounds.


Patent
Theravance | Date: 2016-09-20

In one aspect, the invention relates to compounds having the formula: where R^(1), R^(2a), R^(2b), R^(3)-R^(6), a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.


Patent
Theravance | Date: 2016-07-11

The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.


The invention provides novel quinolinone-carboxamide 5-HT_(4 )receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT_(4 )receptor activity, and processes and intermediates useful for preparing such compounds.


Patent
Theravance | Date: 2016-07-21

In one aspect, the invention relates to compounds having the formula: where R^(1), R^(2), R^(3), R^(4), and R^(5 )are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.


Patent
Theravance | Date: 2016-06-06

In one aspect, the invention relates to compounds having the formula: where R^(1)-R^(6), a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.


Patent
Theravance | Date: 2016-04-06

In one aspect, the invention relates to compounds having the formula: where R^(1)-R^(6), a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.


Patent
Theravance | Date: 2016-02-10

The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.

Loading Theravance collaborators
Loading Theravance collaborators